| abstract |
FIELD: chemistry.SUBSTANCE: invention relates to oxazole pyrimidine compounds of formulain any of stereomeric forms thereof or a physiologically acceptable salt thereof, where A is O; X is (C-C)alkanediiyl oxy; Ris (C-C)alkyl; Ris phenylene, optionally substituted at one or two ring carbon atoms with identical or different R; Ris (C-C)alkyl, optionally substituted with 1-3 fluorine atoms, or (C-C) cycloalkyl-CH- (u is selected from 1 and 2), or Ris a residue of a saturated or unsaturated 4-10-member monocyclic or bicyclic ring containing 0, 1, 2 or 3 identical or different heteroatoms in the ring, selected from N, O and S, and is (C-C)cycloalkyl, indanyl, phenylene, naphthyl, isothiazolyl, thiadiazolyl, pyridyl, benzothiazolyl, quinolinyl, tetrahydrofuranyl, where the ring residue is optionally substituted at one or more ring carbon atoms with Rsubstitutes; Ris hydrogen; Ris (C-C)alkyl; Ris selected from a group consisting of a halogen and (C-C) alkyl, which is optionally substituted with 1-3 fluorine atoms, (C-C)alkyloxy, which is optionally substituted with 1-3 fluorine atoms, and (C-C)alkyl-S(O)-, wherein (C-C)alkyl is optionally substituted with 1-3 fluorine atoms; m equals 0. The invention also relates to a pharmaceutical composition containing a compound of formula I, and to a method of producing compounds of formula I.EFFECT: invention provides compounds of formula I, which are intended for EDG-1 receptor activation and wound healing.17 cl, 2 tbl, 2 ex |